Literature DB >> 23226619

Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status.

Liyan Xue1, Xueying Mao, Guoping Ren, Elzbieta Stankiewicz, Sakunthala C Kudahetti, Dongmei Lin, Luis Beltran, Daniel M Berney, Yong-Jie Lu.   

Abstract

We have previously reported genetic differences between Western and Chinese prostate cancers, including different frequencies of ERG rearrangements. We investigated further ERG expression and rearrangements in prostate cancers and high-grade prostatic intraepithelial neoplasia (HGPIN) from the UK and China to determine differences between these two populations by tissue microarray based immunohistochemistry and fluorescence in situ hybridization. In keeping with our previous observation, that ERG was rearranged at a higher frequency in UK prostate cancer samples (38%, 58/155) than Chinese ones (8%, 7/93), ERG rearrangements were also found in 21% (4/19) and 0% (0/19) foci of HGPIN in UK and Chinese samples respectively. ERG nuclear expression in UK cancers (34%, 54/160) was significantly higher than that in Chinese ones (10%, 9/88) (p<0.001). ERG nuclear expression in UK HGPIN (28%, 11/39) was higher than that in Chinese HGPIN (0%, 0/9), but without statistical significance (p=0.193). ERG nuclear expression was correlated to ERG rearrangements in both UK (Kappa=0.686) and Chinese (Kappa=0.565) cancers. These data demonstrate that ERG rearrangement and expression frequencies are different in prostate cancers from UK and China as early as the precursor lesion, HGPIN. The nuclear expression is associated with ERG rearrangements which mainly occur in the Western samples. UK and Chinese prostate cancers may be the result of different genetic mechanisms.

Entities:  

Keywords:  ERG; genomic rearrangement; high-grade prostatic intraepithelial neoplasia; prostate cancer; protein expression

Year:  2012        PMID: 23226619      PMCID: PMC3512186     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  37 in total

1.  TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Authors:  Cristina Magi-Galluzzi; Toyonori Tsusuki; Paul Elson; Kelly Simmerman; Chris LaFargue; Raquel Esgueva; Eric Klein; Mark A Rubin; Ming Zhou
Journal:  Prostate       Date:  2010-09-28       Impact factor: 4.104

2.  Antibody-based detection of ERG rearrangement-positive prostate cancer.

Authors:  Kyung Park; Scott A Tomlins; Kumaran M Mudaliar; Ya-Lin Chiu; Raquel Esgueva; Rohit Mehra; Khalid Suleman; Sooryanarayana Varambally; John C Brenner; Theresa MacDonald; Abhishek Srivastava; Ashutosh K Tewari; Ubaradka Sathyanarayana; Dea Nagy; Gary Pestano; Lakshmi P Kunju; Francesca Demichelis; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

3.  TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients.

Authors:  Kyoungbun Lee; Ji Youn Chae; Cheol Kwak; Ja Hyeon Ku; Kyung Chul Moon
Journal:  Urology       Date:  2010-08-30       Impact factor: 2.649

4.  Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.

Authors:  Xueying Mao; Yongwei Yu; Lara K Boyd; Guoping Ren; Dongmei Lin; Tracy Chaplin; Sakunthala C Kudahetti; Elzbieta Stankiewicz; Liyan Xue; Luis Beltran; Manu Gupta; R Tim D Oliver; Nick R Lemoine; Daniel M Berney; Bryan D Young; Yong-Jie Lu
Journal:  Cancer Res       Date:  2010-06-01       Impact factor: 12.701

5.  ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

Authors:  Yohei Miyagi; Takeshi Sasaki; Kiyoshi Fujinami; Jinyu Sano; Yutaka Senga; Takeshi Miura; Yoichi Kameda; Yuji Sakuma; Yoshiyasu Nakamura; Masaoki Harada; Eiju Tsuchiya
Journal:  Mod Pathol       Date:  2010-08-06       Impact factor: 7.842

6.  Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.

Authors:  L Bonaccorsi; G Nesi; F Nuti; M Paglierani; C Krausz; L Masieri; S Serni; L Proietti-Pannunzi; Y Fang; S C Jhanwar; C Orlando; M Carini; G Forti; E Baldi; L Luzzatto
Journal:  J Endocrinol Invest       Date:  2009-05-05       Impact factor: 4.256

7.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.

Authors:  Bo Han; Rohit Mehra; Robert J Lonigro; Lei Wang; Khalid Suleman; Anjana Menon; Nallasivam Palanisamy; Scott A Tomlins; Arul M Chinnaiyan; Rajal B Shah
Journal:  Mod Pathol       Date:  2009-05-01       Impact factor: 7.842

Review 8.  ETS gene fusions in prostate cancer.

Authors:  Jeremy P Clark; Colin S Cooper
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

9.  The role of the ETS factor erg in zebrafish vasculogenesis.

Authors:  Felix Ellett; Benjamin T Kile; Graham J Lieschke
Journal:  Mech Dev       Date:  2008-11-08       Impact factor: 1.882

10.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Authors:  B Furusato; S-H Tan; D Young; A Dobi; C Sun; A A Mohamed; R Thangapazham; Y Chen; G McMaster; T Sreenath; G Petrovics; D G McLeod; S Srivastava; I A Sesterhenn
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-06-29       Impact factor: 5.554

View more
  13 in total

Review 1.  Prostate cancer research in China.

Authors:  Shan-Cheng Ren; Rui Chen; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2013-04-22       Impact factor: 3.285

2.  TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.

Authors:  Hui Jiang; Xueying Mao; Xiaoyi Huang; Jing Zhao; Lumei Wang; Jingjing Xu; Hongwei Zhang; Yongjie Lu; Yongwei Yu
Journal:  Tumour Biol       Date:  2016-06-20

Review 3.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

4.  High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer.

Authors:  Yanling Zhang; Xue-Ying Mao; Xiaoyan Liu; Rong-Rong Song; Daniel Berney; Yong-Jie Lu; Guoping Ren
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.

Authors:  Gregory M Kelly; Yink Heay Kong; Albert Dobi; Shiv Srivastava; Isabell A Sesterhenn; Rajadurai Pathmanathan; Hui Meng Tan; Shyh-Han Tan; Sok Ching Cheong
Journal:  Mol Clin Oncol       Date:  2014-09-18

6.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

Authors:  Jie Li; Emma Mercer; Xin Gou; Yong-Jie Lu
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

Review 7.  The structure and function of NKAIN2-a candidate tumor suppressor.

Authors:  Shan-Chao Zhao; Bo-Wei Zhou; Fei Luo; Xueying Mao; Yong-Jie Lu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 8.  Effect of Carotene and Lycopene on the Risk of Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies.

Authors:  Yulan Wang; Ran Cui; Yuanyuan Xiao; Juemin Fang; Qing Xu
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

Review 9.  The molecular basis for ethnic variation and histological subtype differences in prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein; Jiaoti Huang
Journal:  Sci China Life Sci       Date:  2013-07-13       Impact factor: 6.038

Review 10.  Prostate cancer in East Asia: evolving trend over the last decade.

Authors:  Yao Zhu; Hong-Kai Wang; Yuan-Yuan Qu; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.